These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 3932097

  • 1. Acute ovarian responses to a long-acting agonist of gonadotropin-releasing hormone in ovulatory women and women with polycystic ovarian disease.
    DeFazio J, Meldrum DR, Lu JK, Vale WW, Rivier JE, Judd HL, Chang RJ.
    Fertil Steril; 1985 Oct; 44(4):453-9. PubMed ID: 3932097
    [Abstract] [Full Text] [Related]

  • 2. Gonadotropin-releasing hormone (GnRH) analog suppression renders polycystic ovarian disease patients more susceptible to ovulation induction with pulsatile GnRH.
    Filicori M, Campaniello E, Michelacci L, Pareschi A, Ferrari P, Bolelli G, Flamigni C.
    J Clin Endocrinol Metab; 1988 Feb; 66(2):327-33. PubMed ID: 3123511
    [Abstract] [Full Text] [Related]

  • 3. Steroid secretion in polycystic ovarian disease after ovarian suppression by a long-acting gonadotropin-releasing hormone agonist.
    Chang RJ, Laufer LR, Meldrum DR, DeFazio J, Lu JK, Vale WW, Rivier JE, Judd HL.
    J Clin Endocrinol Metab; 1983 May; 56(5):897-903. PubMed ID: 6403570
    [Abstract] [Full Text] [Related]

  • 4. Successful induction of ovulation and conception with combined gonadotropin-releasing hormone agonist plus highly purified follicle-stimulating hormone in patients with polycystic ovarian disease.
    Lanzone A, Fulghesu AM, Spina MA, Apa R, Menini E, Caruso A, Mancuso S.
    J Clin Endocrinol Metab; 1987 Dec; 65(6):1253-8. PubMed ID: 3119655
    [Abstract] [Full Text] [Related]

  • 5. Recovery of hormone secretion after chronic gonadotropin-releasing hormone agonist administration in women with polycystic ovarian disease.
    de Ziegler D, Steingold K, Cedars M, Lu JK, Meldrum DR, Judd HL, Chang RJ.
    J Clin Endocrinol Metab; 1989 Jun; 68(6):1111-7. PubMed ID: 2524501
    [Abstract] [Full Text] [Related]

  • 6. GnRH analog administration in patients with polycystic ovarian disease.
    Meden-Vrtovec H.
    Int J Gynaecol Obstet; 1995 Aug; 50(2):179-83. PubMed ID: 7589755
    [Abstract] [Full Text] [Related]

  • 7. The abnormal response of polycystic ovarian disease patients to exogenous pulsatile gonadotropin-releasing hormone: characterization and management.
    Filicori M, Flamigni C, Campaniello E, Valdiserri A, Ferrari P, Meriggiola MC, Michelacci L, Pareschi A.
    J Clin Endocrinol Metab; 1989 Oct; 69(4):825-31. PubMed ID: 2506216
    [Abstract] [Full Text] [Related]

  • 8. Comparison of the effects of ovarian cauterization and gonadotropin-releasing hormone agonist and oral contraceptive therapy combination on endocrine changes in women with polycystic ovary disease.
    Taskin O, Yalcinoglu AI, Kafkasli A, Burak F, Ozekici U.
    Fertil Steril; 1996 Jun; 65(6):1115-8. PubMed ID: 8641482
    [Abstract] [Full Text] [Related]

  • 9. Specific factors predict the response to pulsatile gonadotropin-releasing hormone therapy in polycystic ovarian syndrome.
    Gill S, Taylor AE, Martin KA, Welt CK, Adams JM, Hall JE.
    J Clin Endocrinol Metab; 2001 Jun; 86(6):2428-36. PubMed ID: 11397835
    [Abstract] [Full Text] [Related]

  • 10. Changing pituitary reactivity to follicle-stimulating hormone and luteinizing hormone-releasing hormone after induced ovulatory cycles and after anovulation in patients with polycystic ovarian disease.
    Blankstein J, Rabinovici J, Goldenberg M, Shaley J, Mehta A, Serr DM, Mashiach S.
    J Clin Endocrinol Metab; 1987 Dec; 65(6):1164-7. PubMed ID: 3119650
    [Abstract] [Full Text] [Related]

  • 11. Long-term administration of gonadotropin-releasing hormone agonist and dexamethasone: assessment of the adrenal role in ovarian dysfunction.
    Cedars MI, Steingold KA, de Ziegler D, Lapolt PS, Chang RJ, Judd HL.
    Fertil Steril; 1992 Mar; 57(3):495-500. PubMed ID: 1531463
    [Abstract] [Full Text] [Related]

  • 12. LH suppression following different low doses of the GnRH antagonist ganirelix in polycystic ovary syndrome.
    Hohmann FP, Laven JS, Mulders AG, Oberyé JJ, Mannaerts BM, de Jong FH, Fauser BC.
    J Endocrinol Invest; 2005 Dec; 28(11):990-7. PubMed ID: 16483177
    [Abstract] [Full Text] [Related]

  • 13. Pituitary function is altered during the same cycle in women with polycystic ovary syndrome treated with continuous or cyclic oral contraceptives or a gonadotropin-releasing hormone agonist.
    Ruchhoft EA, Elkind-Hirsch KE, Malinak R.
    Fertil Steril; 1996 Jul; 66(1):54-60. PubMed ID: 8752611
    [Abstract] [Full Text] [Related]

  • 14. Ovulation induction with human menopausal gonadotropin versus follicle-stimulating hormone after pituitary suppression by gonadotropin releasing hormone agonist in polycystic ovary disease. A cross-over study.
    Fulghesu AM, Lanzone A, Guida C, Nicoletti MC, Rossi P, Le Donne M, Caruso A, Mancuso S.
    J Reprod Med; 1992 Oct; 37(10):834-40. PubMed ID: 1479563
    [Abstract] [Full Text] [Related]

  • 15. Adrenal and ovarian steroid hormone responses to gonadotropin-releasing hormone agonist treatment in polycystic ovary syndrome.
    Gonzalez F, Hatala DA, Speroff L.
    Am J Obstet Gynecol; 1991 Sep; 165(3):535-45. PubMed ID: 1832519
    [Abstract] [Full Text] [Related]

  • 16. Endocrine response determines the clinical outcome of pulsatile gonadotropin-releasing hormone ovulation induction in different ovulatory disorders.
    Filicori M, Flamigni C, Meriggiola MC, Ferrari P, Michelacci L, Campaniello E, Valdiserri A, Cognigni G.
    J Clin Endocrinol Metab; 1991 May; 72(5):965-72. PubMed ID: 1902487
    [Abstract] [Full Text] [Related]

  • 17. Gonadotropin-releasing hormone antagonist versus agonist administration in women undergoing controlled ovarian hyperstimulation: cycle performance and in vitro steroidogenesis of granulosa-lutein cells.
    Minaretzis D, Alper MM, Oskowitz SP, Lobel SM, Mortola JF, Pavlou SN.
    Am J Obstet Gynecol; 1995 May; 172(5):1518-25. PubMed ID: 7755066
    [Abstract] [Full Text] [Related]

  • 18. Failure to improve ovarian response by combined gonadotropin-releasing hormone agonist and gonadotropin therapy.
    Bider D, Kokia E, Lipitz S, Blankstein J, Mashiach S, Serr DM, Ben-Rafael Z.
    Gynecol Obstet Invest; 1990 May; 29(3):192-6. PubMed ID: 2113505
    [Abstract] [Full Text] [Related]

  • 19. The use of gonadotrophin-releasing hormone antagonists in polycystic ovarian disease.
    Lubin V, Charbonnel B, Bouchard P.
    Baillieres Clin Obstet Gynaecol; 1998 Dec; 12(4):607-18. PubMed ID: 10627771
    [Abstract] [Full Text] [Related]

  • 20. Effect of mifepristone (RU486) on the pituitary response to gonadotrophin releasing hormone in women.
    Kazem R, Messinis LE, Fowler P, Groome NP, Knight PG, Templeton AA.
    Hum Reprod; 1996 Dec; 11(12):2585-90. PubMed ID: 9021355
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.